Pharmaceutical composition containing a Sanbakuso fraction and its manufacturing method
A specific production method for Saururus chinensis and Trigonium oleracea fractions addresses the inadequacies of IBD treatments by enhancing mucin production and strengthening intestinal junctions, effectively suppressing inflammation and improving intestinal health.
Patent Information
- Application Number
- JP2022578876
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-06-17
- Filing Date
- 2021-06-17
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2041-06-17
AI Technical Summary
Current treatments for inflammatory bowel diseases (IBD) are inadequate, lacking fundamental therapeutic agents and causing side effects, while mucosal healing is essential for intestinal health, focusing on restoring mucin production and tight junctions between intestinal epithelial cells.
A specific production method involving ethanol extraction, enzymatic treatment, and fractionation of Saururus chinensis and Trigonium oleracea fractions to produce active polysaccharides that enhance mucin production and strengthen tight junctions, using enzymes like pectinase and polygalacturonase to separate active components.
The produced fractions effectively suppress inflammation, enhance mucin production, and strengthen intestinal epithelial cell junctions, demonstrating therapeutic benefits in inflammatory bowel disease models by reducing pro-inflammatory cytokines and improving intestinal health.
Smart Images

Figure 0007590721000005 
Figure 0007590721000006 
Figure 0007590721000007
Abstract
Description
Detailed Description of the Invention
[0001] [Technical field] The present invention relates to a method for preparing an active fraction of Saururus chinensis. The present invention also relates to a pharmaceutical composition containing the Saururus chinensis fraction prepared by the specific preparation method. The present invention also relates to a medical use of the Saururus chinensis fraction prepared by the specific preparation method for treating inflammatory bowel disease.
[0002] This patent application claims priority to Korean Patent Application No. 10-2020-0073480, filed with the Korean Intellectual Property Office on June 17, 2020, the disclosure of which is incorporated herein by reference. [Background technology]
[0003] Dysregulation of inflammatory responses can induce chronic inflammation and cause various diseases such as rheumatoid arthritis, atherosclerosis, and asthma. Colitis is a disease in which inflammation occurs in the large intestine, and includes inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Inflammatory bowel disease (IBD) is represented by ulcerative colitis (UC) and Crohn's disease (CD). The prevalence of inflammatory bowel disease is increasing worldwide, and the rate of increase is higher in Asian countries than in Western countries. Inflammatory bowel disease is a chronic disease that requires lifelong management.
[0004] Mucosal biopsies from IBD patients show increased expression of pro-inflammatory cytokines, chemokines, and intercellular adhesion molecule 1 (ICAM-1), as well as loss of mucus and reduced tight junctions between epithelial cells. Currently, representative drugs used to treat inflammatory bowel disease include 5-aminosalicylic acid, corticosteroids, immunomodulators, and anti-tumor necrosis factor-α agents (anti TNF-α). These drugs are used in stages according to clinical guidelines because they exert their effects through different mechanisms of action, but it is difficult to consider them as fundamental treatments, and various side effects have been reported.
[0005] Mucosal healing has recently emerged as a treatment goal for inflammatory bowel disease. The most notable characteristic of patients with inflammatory bowel disease is reduced mucin production in the large intestine. The absence of a mucus layer allows bacteria to reach intestinal epithelial cells directly, which causes severe inflammatory reactions (Johansson, ME (2014) Mucus layers in inflammatory bowel disease. Inflammatory bowel diseases 20, 2124-2131). To fundamentally improve intestinal function, mucosal production must be restored, and the strength of the tight junctions between intestinal epithelial cells is also very important. Therefore, research into mucosal production has been actively conducted recently. Therefore, in order to treat IBD and maintain healthy intestinal function, inflammation suppression, normal recovery of the mucus layer, and restoration of the strength of the tight junctions of intestinal epithelial cells must be properly carried out. However, currently there is no effective treatment for inflammatory bowel disease, and only symptom-relieving drugs are prescribed. The number of patients is increasing, and there is an urgent need to develop a treatment that meets these demands.
[0006] Meanwhile, Saururus chinensis is a perennial herb belonging to the Sauraceae family, and is known in the folklore to have various effects when used in its entirety or with its roots and leaves. [Summary of the invention] [Problem to be solved by the invention]
[0007] Therefore, an object of the present invention is to provide a pharmaceutical or functional health food composition using Sanpakuso for treating, improving or preventing inflammatory bowel disease.
[0008] Another problem to be solved by the present invention is to provide a method for producing a Sanbikusa extract or a fraction thereof which is excellent in the therapeutic, ameliorative or preventive effect on inflammatory bowel disease.
[0009] Another problem to be solved by the present invention is to provide a medicinal use of a Sanpakuso fraction produced by a specific production method.
[0010] Another problem to be solved by the present invention is to provide a method for treating inflammatory bowel disease, comprising the step of administering to an individual in need thereof a pharmaceutical composition for treating, ameliorating or preventing inflammatory bowel disease using the above-mentioned Sanpakuso. [Means for solving the problem]
[0011] In order to solve the above problems, the present invention provides
[0012] (S1) extracting Sanpakuso with 50 to 90 volume percent ethanol aqueous solution;
[0013] (S2) adding purified water to the residue remaining after the extraction and heating at 70 to 100°C, preferably 80 to 100°C, more preferably 90 to 100°C;
[0014] (S3) enzymatically treating the result of step (S2);
[0015] (S4) removing residue from the extract and filtering it;
[0016] (S5) adding ethanol to the filtrate of step (S4) to form a precipitate; and
[0017] (S6) recovering the precipitate;
[0018] The present invention provides a method (Method 1) for producing a Sanpakuso fraction (SCEP2) that is useful for inflammatory bowel disease.
[0019] In the above-mentioned method 1 according to the present invention, the above-mentioned enzyme plays a role of isolating the active polysaccharide components present in Sanpakuso, and is preferably pectinase (pectinase or polygalacturonase), pectinesterase, pectin lyase, Arabinanase ( Arabinase One or more enzymes selected from the group including , xylanase, beta-glucanase and cellulase can be used alone or in combination. More preferably, the enzyme is polygalacturonase, pectin lyase or a mixture thereof, and even more preferably, the enzyme is a mixture of polygalacturonase and pectin lyase.
[0020] For example, commercial enzymes such as Pectinex® Ultra SP-L (polygalacturonase), Pectinex® Ultra MASH (pectin lyase), Rapidase C80Max (pectinase, Arabinase ), Viscozyme L( Endo-1,3(4)-beta-glucanase ,Xylanase,cellulase,hemicellulase, ArabinaseOne or more enzymes selected from the group consisting of Pectinex® Ultra SP-L and Pectinex® Ultra MASH can be used alone or in combination. It is more preferable to use Pectinex® Ultra SP-L and Pectinex® Ultra MASH alone or in combination.
[0021] The enzyme treatment can be carried out by adding 0.05 to 5 parts by weight of enzyme per part by weight of Sanpakuso. If the amount of enzyme is less than 0.05 parts by weight, the amount of enzyme is too small, resulting in a reduced recovery rate of the active polysaccharides present in Sanpakuso. If the amount of enzyme exceeds 5 parts by weight, excessive enzyme action may reduce the efficacy of the active polysaccharides, which is undesirable.
[0022] In the enzyme treatment, the reaction time is preferably 6 to 96 hours, more preferably 12 to 72 hours. In the enzyme treatment, the temperature and pH are preferably set under optimal conditions for each enzyme, in order to obtain the active polysaccharide component with the highest recovery rate. If the reaction time of the enzyme treatment is less than 6 hours, the time for enzyme treatment is too short, resulting in a decrease in the recovery rate, and if it exceeds 96 hours, it is not preferable because the efficacy of the active polysaccharide may be reduced due to excessive enzyme treatment.
[0023] In the above-mentioned method 1 according to the present invention, the above-mentioned step S5 is preferably a step of concentrating the filtrate, adding ethanol in an amount greater than that of the concentrate (preferably 2 to 8 times by volume), and stirring the mixture to form a precipitate. In this step, the precipitate can be formed by leaving the reaction solution to stand.
[0024] In the above-mentioned method 1 according to the present invention, the step of recovering the precipitate in the above-mentioned step S6 can be carried out, for example, by centrifugation. The recovered precipitate can be used as a raw material for the manufacture of pharmaceuticals after being concentrated and freeze-dried.
[0025] The present invention also relates to
[0026] (S1) extracting Sanpakuso with 50 to 90 volume percent ethanol aqueous solution;
[0027] (S2) filtering and concentrating the extract;
[0028] (S3) passing the concentrate through a resin-filled column and separating the components based on whether they are adsorbed by the resin;
[0029] (S4) Recovering components that are eluted with a water and ethanol concentration gradient from the components adsorbed to the resin;
[0030] The present invention provides a method (Method 2) for producing a Sanpakuso fraction (SCESII-1) that is useful for inflammatory bowel disease.
[0031] More specifically, the above three fractions are obtained as follows.
[0032] Fraction 1 (SCESII-1): Elution is started with 20-40% by volume (preferably 30%) ethanol, and when the collected eluate reaches about 1.5-2.5 (preferably 2 times) the packed volume, collection is interrupted and the elution solvent is changed to 60-80% by volume (preferably 70%) ethanol. This is the fraction before the elution solvent is changed to 60-80% by volume ethanol. Preferably, the eluate is passed at room temperature at a flow rate of 1 packed volume (bed volume, BV) per unit time to collect the eluate.
[0033] Fraction 2 (SCESII-2): Elute with 60-80% by volume (preferably 70%) ethanol and collect it. When the eluate reaches about 1.5-2.5 (preferably 2 times) the packing volume (BV), discontinue collection and change the elution solvent to 100% ethanol.
[0034] Fraction 3 (SCESII-3): Start elution with 100% ethanol and collect it. Collect the eluate until it reaches about 2.5 to 3.5 (preferably 3 times) the packing volume (BV).
[0035] The present invention also provides a method for producing a method for manufacturing a semiconductor device comprising the steps of:
[0036] (S1) extracting Sanpakuso with 50 to 90 volume percent ethanol aqueous solution;
[0037] (S2) filtering and concentrating the extract;
[0038] (S3) separating the concentrate according to polarity using a resin;
[0039] (S4) Provided is a method (Method 3) for producing a Sanpakuso fraction (SCESII-4) useful for inflammatory bowel disease, which includes a step of recovering components that are not adsorbed by the column during the resin separation.
[0040] It has been known that Sanbaikyou extract has various effects such as antioxidant, anti-cancer, and anti-inflammatory, but the inventors have confirmed that ordinary Sanbaikyou extract has almost no effect on inflammatory bowel disease. However, the Sanbaikyou fraction obtained by a specific manufacturing method has a surprising effect on treating or improving inflammatory bowel disease, unlike ordinary Sanbaikyou extract. The inventors have confirmed that the Sanbaikyou active fraction obtained by a specific manufacturing method exhibits effects such as a therapeutic effect on colitis induced by DSS in mice, anti-inflammation, increased mucin production ability, and enhanced tight junction robustness of intestinal epithelial cells, and have confirmed that it is useful for treating inflammatory bowel disease through an examination of colon tissue in which inflammatory bowel disease is induced by DSS, thereby completing the present invention. In addition, the Sanbaikyou fraction obtained by the specific manufacturing method according to the present invention has been confirmed to inhibit the activity of inflammatory cytokines such as TNF-α, IL-1β, and IL-6, thereby completing the present invention.
[0041] As the Sanpakusou, Saururus chinensis, which belongs to the Saururaceae family, can be used.
[0042] Preferably, in the above methods 1 to 3 according to the present invention, the aqueous ethanol solution is a 60 to 80% by volume aqueous ethanol solution, and more preferably, in the above methods 1 to 3 according to the present invention, the aqueous ethanol solution is a 65 to 75% by volume aqueous ethanol solution.
[0043] In the above methods 2 and 3 according to the present invention, preferably, the residue recovered in step S1 is extracted in the same manner as in step S1 under the extraction conditions to recover an extract, which can be used together with the extract from step S1.
[0044] In the above-mentioned methods 2 and 3 according to the present invention, the resin is preferably a highly porous synthetic adsorbent of styrene and DVB (Divinyl benzene) copolymer (e.g., Amberlite XAD-2, Amberlite XAD-4, Amberlite XAD-16N, Amberlite XAD-1180N, TRILITE (registered trademark) GSH-20, TRILITE GSP-25, TRILITE GSP-50, TRILITE GSP-07, DIAION HP20), porous synthetic adsorbents of non-ionic aliphatic acrylic polymers (e.g., Amberlite XAD-7HP), etc. can be used. In the methods 2 and 3 according to the present invention, preferably HP20 from DIAION is used as the resin.
[0045] The Sanbakuso fraction according to the present invention can be prepared in powder form by a conventional drying method such as vacuum drying, spray drying, or freeze drying to remove the remaining lower alcohol and organic solvent so that it can be used as a raw material for pharmaceuticals. Specifically, the Sanbakuso fraction may be in the form of a concentrated liquid or a freeze-dried powder. According to one embodiment of the present invention, the Sanbakuso fraction according to the present invention may be a concentrated liquid soft extract.
[0046] The present invention also provides a pharmaceutical or functional health food composition containing a Sanpakuso fraction obtained by any one of the above methods 1 to 3 according to the present invention.
[0047] The present invention further provides a pharmaceutical or functional health food composition for preventing, treating or ameliorating inflammatory bowel disease, which contains a Sanpakuso fraction obtained by any one of the above methods 1 to 3 according to the present invention.
[0048] In the present invention, the term "inflammatory bowel disease" is a general term for diseases that cause inflammation in the intestinal tract, and specifically may be a chronic recurrent inflammatory disease caused by dysregulation of the immune system in the small intestine and / or large intestine. The inflammatory bowel disease includes ulcerative colitis, Crohn's disease, and irritable bowel syndrome (IBS).
[0049] The pharmaceutical or health functional food composition of the present invention can be formulated into oral dosage forms, such as tablets, troches, lozenges, aqueous or oily suspensions, powders or granules, emulsions, hard or soft capsules, syrups or elixirs, by conventional methods for preventing or treating inflammatory bowel disease.
[0050] For formulation into dosage forms such as tablets and capsules, excipients such as lactose, sucrose, sorbitol, mannitol, starch, milk sugar, microcrystalline cellulose, binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose, disintegrants such as dicalcium phosphate, crospovidone, lubricants such as magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol wax, etc. In the case of capsule dosage forms, in addition to the above-mentioned substances, liquid carriers such as fatty oils may be included.
[0051] Furthermore, the composition of the present invention can be administered parenterally, and parenteral administration can be by subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection. To prepare a parenteral dosage form, the composition is mixed with water together with a stabilizer or buffer to prepare a solution, which can be formulated into a unit dosage form such as an ampoule or a vial.
[0052] The dosage of the pharmaceutical or health functional food composition according to the present invention must be an effective amount to show sufficient therapeutic or prophylactic effects. "Effective amount" means an amount sufficient to prevent or treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be selected by those skilled in the art depending on factors such as the formulation method, the condition and weight of the patient, the patient's sex, age, the degree of the disease, the drug form, the route and period of administration, the excretion rate, reaction sensitivity, etc. The effective amount may vary depending on the route of treatment, the use of excipients, and the possibility of co-administration with other drugs, as recognized by those skilled in the art.
[0053] The dosage of the Sanbakuso fraction according to the present invention may vary depending on the age, physical condition, weight, etc. of the patient, but is generally preferably administered within the range of 10-100 mg / kg (body weight) / day. It may be administered once a day or in several divided doses per day within the effective daily dosage range.
[0054] The health functional food composition according to the present invention can be ingested by being contained in various foods, such as meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, energy drinks, alcoholic beverages, vitamin complexes, etc.
[0055] The present invention also provides a method for treating, preventing or ameliorating inflammatory bowel disease, comprising administering a pharmacologic or prophylactically effective amount of a Sanhakuso fraction produced by a specific production method according to the present invention to an individual in need of such treatment, prevention or amelioration. Preferably, the individual is a human being. [Effects of the invention]
[0056] The present invention provides a method for producing a Sanpakuso fraction useful for treating, ameliorating, or preventing inflammatory bowel disease.The present invention further provides a pharmaceutical or functional health food composition for treating, ameliorating, or preventing inflammatory bowel disease, which contains the Sanpakuso fraction produced by the production method of the present invention as an active ingredient. [Brief description of the drawings]
[0057] The following drawings attached to this specification illustrate preferred embodiments of the present invention and, together with the above-mentioned contents of the invention, serve to further understand the technical concept of the present invention. Therefore, the present invention should not be interpreted as being limited only to the matters depicted in such drawings.
[0058] [Figure 1] Schematic diagram of the process for producing Saururus chinensis fractions. [FIG. 2a and FIG. 2b] These are the results of evaluating the length of mouse large intestine on day 10 of the intestinal inflammation model evaluation after administration of the Sanbaikou fraction (n=8). [Figure 3] Results of observing histological changes in the large intestine after administration of Sanpakuso fraction. [Figure 4] Results of evaluation of TNF-α in colonic tissue after administration of Sanbakuso fraction. [Figure 5] Results of evaluation of MPO in colonic tissue after administration of Sanpakuso fraction. [Figure 6] Results of evaluating the sIgA secretion ability and related cytokine induction ability of Peyer's patch cells in an intestinal inflammation model after administration of a Sanpakuso fraction. [Figure 7] Results of evaluating the effect of an active ingredient fraction from Sanbaikou on intestinal mucus-secreting cells (LS 174T, a human intestinal goblet cell line). [Mode for carrying out the invention]
[0059] Hereinafter, the present invention will be described in detail with reference to examples to aid in understanding the present invention. However, the examples according to the present invention may be modified in various different forms, and the scope of the present invention should not be construed as being limited to the following examples. The examples of the present invention are provided to more completely explain the present invention to those having average knowledge in the field to which the present invention pertains.
[0060] [Production of Sanpakuso Fraction]
[0061] As shown in Figure 1, various fractions were produced.
[0062] Example 1: Production of Sanpakuso hot water extract (SCW)
[0063] Dried and crushed Sanpakuso was mixed with 20 times the volume of purified water and extracted for 2 hours at 100℃. After extraction, the residue was removed using an extraction cloth, and the extract was filtered through Whatman No. 2 filter paper. The filtrate was concentrated using a vacuum concentrator and then freeze-dried to produce Sanpakuso hot water extract (SCW).
[0064] Example 2: Preparation of various organic solvent extracts of Sanbaiko (SCE, SCESII-1, SCESII-2, SCESII-3, SCESII-4)
[0065] Dried and ground Sanpakuso was mixed with 10 times the volume of 70% (v / v) ethanol aqueous solution and extracted at 70°C for 2 hours. After filtering with an extraction cloth, the filtered residue was further extracted under the same conditions. The extract was filtered with Whatman No. 2 filter paper and concentrated using a vacuum concentrator. This was named 70% ethanol extract concentrate SCE. The SCE extract was passed through a column packed with synthetic resin HP20. All components not adsorbed by the resin were collected using purified water, and this component was named SCESII-4. In the next step, the components adsorbed by the resin were eluted in the order of purified water to 30% ethanol by volume, 30 to 70% ethanol by volume, and 70 to 100% ethanol by volume, and collected according to the polarity of the elution solvent. These were named SCESII-1, SCESII-2, and SCESII-3 according to the procedure of the previous elution.
[0066] Example 3: Production of Sanshikuso crude polysaccharide SCEP1, active polysaccharide SCEP2, and low molecular weight sugar SCES fraction
[0067] Sanbakuso was extracted with 70% ethanol aqueous solution, and the remaining residue was mixed with 20 times the volume of purified water and stirred at 100°C for 2 hours. Enzymes (Pectinex® Ultra SP-L and Pectinex® Ultra MASH in a 1:1 weight ratio) were added and reacted at 55°C for 72 hours with stirring. The enzyme reaction solution was inactivated at 100°C for 30 minutes. After removing the residue using an extraction cloth, the extract was filtered through Whatman No. 2 filter paper. This filtrate was named crude polysaccharide SCEP1. This filtrate was concentrated, and then ethanol was added in an amount four times the volume of the concentrate, stirred for 30 minutes, and left to stand at room temperature for 24 hours to form a precipitate. The precipitate was centrifuged, and the precipitate and supernatant were collected. The collected precipitate was concentrated and freeze-dried to produce Sanbakuso SCEP2 active polysaccharide fraction, and the supernatant was concentrated and freeze-dried to produce Sanbakuso SCES low molecular weight sugar fraction.
[0068] [Experimental Example 1: Evaluation of the inflammation suppression effect in an intestinal inflammation model]
[0069] A study was conducted on the inhibitory and therapeutic effects of the active ingredient fraction of Sanbaikou on the development of intestinal inflammation. Inflammatory bowel disease was induced in a BALB / c mouse model using dextran sodium sulfate (DSS). For the experiment, 100 8-week-old male BALB / c mice were purchased and randomly divided into 9 groups. To induce acute colitis in the mice, 5% DSS was dissolved in drinking water and the BALB / c mice were given free access to water for 7 days, while the normal control group (NT: Not Treated) was given free access to drinking water. After one day of DSS feeding, the normal control group and the negative control group (NC: Negative Control) that had only received 5% DSS were given distilled water, and the sample groups were given the respective samples dissolved in distilled water at the doses listed in Table 1 below, which were orally administered once a day for 9 days.
[0070] [Table 1]
[0071] The degree of induction of colitis (disease activity index, DAI) was calculated based on the scores shown in Table 2 below by visually checking the weight loss, degree of loose stool, bloody stool, and the presence or absence of blood in the anus every two days.
[0072] Calculation formula:
[0073] DAI = weight loss score + stool consistency score + blood in stool score + blood in anus score
[0074] Screening system for disease activity index (DAI) indicators
[0075] [Table 2]
[0076] The evaluation results are shown in Table 3 below.
[0077] [Table 3]
[0078] As a result of measuring the change in DAI in each administration group, the DAI score increased from the second day in all groups except the normal control group, but the low molecular weight active substance fraction SCESII-1 and the active polysaccharide fraction SCEP2 showed significantly lower DAI scores than the negative control group (NC) on the eighth day, confirming their colitis-suppressing effect. On the other hand, the other fractions and Sanpakuso water extract had almost no effect.
[0079] Since DAI is measured based on factors such as body weight, stool condition, and degree of bloodstains, DAI may be a more important evaluation factor in some cases.
[0080] On day 10 of the experiment, the mice were sacrificed and the lengths of the large and small intestines and the weights of the spleens were measured and evaluated. The results are summarized in Figure 2.
[0081] Mice were sacrificed and their colon lengths were measured. The colon length of NC mice, which had been fed 5% DSS alone, was reduced by about 32% compared to the negative control group, which had not been fed DSS. However, the low molecular weight active fractions SCESII-I, SCESII-4, and the active polysaccharide fraction SCEP2 recovered the colon length to almost the same length as that of the normal NT group. This indicates that the colitis was dramatically improved compared to the negative control group. In particular, the active polysaccharide fraction SCEP2 and the low molecular weight active fraction SCEII-I derived from Sanbaikou showed very similar colon lengths between mice, which was considered to be a high reliability of the experiment. In contrast, the experimental groups that received other extracts or fractions, including Sanbaikou water extract and alcohol extract, showed colon lengths similar to those of NC or showed slight recovery, confirming that they had no effect.
[0082] In particular, all mice in the 5% DSS-only group (NC) had loose stools and bloody stools, whereas the active polysaccharide fraction SCEP2 did not produce looser stools than the NC group, and only occult blood was observed in three mice. This indicates that the active polysaccharide derived from Sanbaiko has an excellent therapeutic effect against colitis. Taking the above results together, the active polysaccharide fraction SCEP2 and the low molecular weight active fraction SCEII-I were confirmed to have colitis-suppressing activity, as the DAI score returned to normal levels and the colon length increased relatively, unlike the negative control group (NC) that had only ingested 5% DSS.
[0083] [Experimental Example 2: Observation of histological changes in the large intestine after administration of Sanpakuso fraction]
[0084] After autopsy, the colons removed for histological examination were fixed in 10% formaldehyde solution, and embedded in paraffin after general tissue processing. Each embedded tissue was sliced at 5.0 μm using a microtome (Leica, Wetzlar, Germany), stained with alcian blue, and each slice was treated with Canadian balsam and observed under an optical microscope (Olympus BX53 microscope (Olympus Corp., Tokyo, Japan)). The results are shown in Figure 3.
[0085] As shown in Figure 3, in the group treated with dextran sulfate sodium, the tissue damage due to inflammation was severe, the inflammation continued to the mucosa, and the damage to the entire intestinal gland and epithelial cells occurred severely. However, in the groups administered with the active polysaccharide fraction SCEP2, the low molecular weight active fraction SCEII-I, and the low molecular weight active fraction SCEI-4, the tissue findings were found to be significantly improved.
[0086] [Experimental Example 3: Evaluation of MPO and TNF-α in colonic tissue after administration of Sanpakuso fraction]
[0087] TNF-α and myeloperoxidase (MPO) were analyzed in colitis-induced colonic tissues. Colonic tissue samples were placed in lysis buffer (Intron, Seoul, Korea) and ground using a homogenizer (Scilogex, Rockyhill, CT, USA). They were centrifuged at 10,000 rpm for 20 min at 4°C, and the supernatant was collected, and TNF-α and MPO contents were measured using ELISA kits according to the manufacturer's guidelines. The results are shown in Figures 4 and 5.
[0088] As a result, the active polysaccharide fraction SCEP2 and the low molecular weight active fraction SCESII-1 were found to have a very excellent effect in reducing the production of the main inflammatory factor TNF-α. Furthermore, it was confirmed that the polysaccharide fraction SCEP2 and the low molecular weight active fractions SCESII-1 and 3 significantly inhibited the production of MPO, which is involved in macrophage activation.
[0089] [Experimental Example 4: Evaluation of sIgA secretion and related cytokine induction by Peyer's patch cells in an intestinal inflammation model]
[0090] 62-1 week old C3H / HeN mice were divided into groups of 6 mice each and orally administered the Sanpakuso fraction 10 times (once every 2 days) over a period of 20 days. Peyer's patch cells were collected from the mice and cultured in 96-well plates for 3 days, and sIgA produced by Peyer's patch cells activated by oral administration was analyzed by ELISA. After oral administration was completed, the small intestines were removed from the mice and feces were collected, and sIgA production was analyzed by ELISA. The results are shown in Figure 6.
[0091] As a result of the evaluation, it was confirmed that the production of slgA was increased in the active polysaccharide fraction SCEP2, the crude polysaccharide SCEP1, the low molecular weight active fraction SCESII-1, and the low molecular weight active fraction SCESII-4.
[0092] [Experimental Example 5: Evaluation of SCFA production ability induced in feces by oral administration of Sanpakuso active fraction]
[0093] After oral administration, the cecum of the mice was collected and diluted with 80% methanol to a final concentration of 1 g / mL, then filtered through a 0.45 μm syringe filter and the production of five short-chain fatty acids (acetic acid, propionic acid, butyric acid, valeric acid, and heptanoic acid) was confirmed using gas chromatography (GC) equipped with a DBFFAP capillary column. The results are shown in Table 4 below.
[0094] It was confirmed that the fecal active polysaccharide fraction SCEP2 and the low molecular weight active fraction SCESII-1 increased the production of SCFA in a concentration-dependent manner. The positive control sulfasalazine actually reduced the production of SCFA.
[0095] [Table 4]
[0096] [Experimental Example 6: Effects of the active ingredient fraction of Sanpakuso on intestinal mucus-secreting cells (LS 174T, a human intestinal goblet cell line)]
[0097] BALB / c mice were provided with water containing 5% DSS for 7 days and orally administered the experimental samples for 8 days. The experimental animals were sacrificed for histological analysis. The colons were sectioned and fixed with 10% formalin solution, then filled with paraffin. Sections were prepared at a thickness of 5 μm, stained with Alcian Blue (AB) stain, and mounted with Canada balsam. Each slide was observed using a light microscope (40X magnification). Images were analyzed using MetaMorph software (Molecular Devices, Sunnyvale, CA, USA). The results are shown in Figure 7.
[0098] As a result, it was confirmed that in the case of the active polysaccharide fraction SCEP2, the low molecular weight active fraction SCESII-I, and the low molecular weight active fraction SCEI-4, the amount of mucin (stained blue by Alcian blue) secreted from goblet cells was restored to a level similar to that of the normal group, compared to the normal group not treated with DSS. [Industrial Applicability]
[0099] The present invention relates to a composition for preventing, treating or ameliorating inflammatory bowel disease, which contains a specific fraction produced from Sanpakuso as an active ingredient, and a method for producing the same. [Brief description of the drawings]
[0100] [Figure 1] 1 is a schematic diagram showing the process for producing a Saururus chinensis fraction. [Figure 2a] The results show the results of evaluating the length of mouse colon on day 10 of an intestinal inflammation model evaluation after administration of the Sanbakuso fraction (n=8). [Figure 2b] The results show the results of evaluating the length of mouse colon on day 10 of an intestinal inflammation model evaluation after administration of the Sanbakuso fraction (n=8). [Diagram 3] This shows the results of observing histological changes in the large intestine after administration of a Sanpakuso fraction. [Figure 4]This shows the results of evaluating TNF-α in colon tissue after administration of Sanpakuso fraction. [Diagram 5] This shows the results of evaluating MPO in colon tissue after administration of Sanpakuso fraction. [Figure 6] These are the results of evaluating the sIgA secretion ability and related cytokine induction ability of Peyer's patch cells in an intestinal inflammation model after administration of a Sanbakuso fraction. [Figure 7] These are the results of evaluating the effect of an active ingredient fraction from Sanbaicou on intestinal mucus-secreting cells (LS 174T, a human intestinal goblet cell line).
Claims
1. (S1) extracting Sanpakuso with 50-90 volume% ethanol aqueous solution; (S2) After the extraction, purified water is added to the remaining residue and heated at 70 to 100°C. (S3) treating the resultant of step (S2) with an enzyme; (S4) removing residue from the result of (S3) and filtering; (S5) adding ethanol to the filtrate of step (S4) to form a precipitate; and (S6) recovering the precipitate; The enzyme is polygalacturonase, pectin lyase or a mixture thereof; A method for producing a Sanpakuso fraction useful for inflammatory bowel disease.
2. The method of claim 1, wherein the ethanol aqueous solution in step S1 is a 60 to 80 volume % ethanol aqueous solution.
3. The method of claim 1, wherein the step (S5) comprises concentrating the filtrate, adding more ethanol than the concentrate, and stirring the mixture to form a precipitate.
4. The method according to claim 1 , further comprising concentrating and freeze-drying the precipitate after step (S6).
5. (S1) extracting Sanpakuso with 50-90 volume% ethanol aqueous solution; (S2) filtering and concentrating the extract; (S3) passing the concentrate through a resin-packed column and separating the components based on whether they are adsorbed by the resin; (S4) recovering components that are eluted in a 20 to 40% by volume aqueous ethanol solution range according to a water and ethanol concentration gradient from among the components adsorbed by the resin; The resin is a porous synthetic adsorbent of a copolymer of styrene and DVB (Divinyl benzene), or a porous synthetic adsorbent of a non-ionic aliphatic acrylic polymer. A method for producing a Sanpakuso fraction useful for inflammatory bowel disease.
6. The method according to claim 5, wherein the ethanol aqueous solution in the step S1 is a 60 to 80 volume % ethanol aqueous solution.
Citation Information
Patent Citations
Compositions containing melissa leaf extract with anti-angiogenic and matrix metalloproteinase inhibitory activity
JP2004520294A
Anti-glycation composition
JP2021031424A
Composition having brain function and congnitionenhancing activity
KR1020040008975A
Method for preparing high bioactive flavonoid compound and method for rapid isolating quercetin therefrom
KR1020100090737A
Composition for preventing or treating inflammatory bowel disease comprising Saururus chinenesis extracts
KR1020150142213A
